EXAS · Categories · M&A
EXAS - Mergers and acquisitions
Exact Sciences Corporation (EXAS) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for EXAS
- Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening TestsExact Sciences acquires exclusive rights to current and future versions of Freenome's blood-based colorectal cancer screening tests Freenome submitted the final module of the premarket approval application to the FDA for the first-version test Strengthens Exact Sciences' leadership in colorectal cancer screening by adding blood-based testing to complement Cologuard Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a biotechnology company pioneering an early cancer detection platform, today announced they have entered into an agreement under which Exact Sciences will acquire exclusive rights in the United States to current an
- Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More PatientsMADISON, Wis., Jan. 9, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ:EXAS) announced today it has acquired PreventionGenetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT). PreventionGenetics provides the clinical lab, expertise, and foundational technology necessary to accelerate the availability of HCT and help more patients know their germline risk of cancer and other diseases. "PreventionGenetics is a natural fit with Exact Sciences, and we're thrilled to have their